| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/03/2001 | WO2001030361A1 Antisense modulation of cytohesin-2expression |
| 05/03/2001 | WO2001030360A1 Modulation of l-selectin shedding via inhibition of tumor necrosis factor alpha converting enzyme (tace) |
| 05/03/2001 | WO2001030359A1 Cholesterol lowering and blood lipids lowering composition |
| 05/03/2001 | WO2001030358A1 Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same |
| 05/03/2001 | WO2001030357A1 Hormonal composition based on a progesterone and an oestrogen and use thereof |
| 05/03/2001 | WO2001030356A1 Hormonal composition based on a progestational agent and an oestrogen and use thereof |
| 05/03/2001 | WO2001030355A1 Contraceptive medicine based on a progestational agent and an oestrogen and preparation method |
| 05/03/2001 | WO2001030354A1 REGULATION OF Apob FOR DIAGNOSIS, TREATMENT AND DRUG SCREENING FOR CARDIOVASCULAR AND METABOLIC DISORDERS OR SYNDROMES |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030352A1 High dose folic acid for the treatment of hyperhomocysteinemia |
| 05/03/2001 | WO2001030351A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | WO2001030350A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | WO2001030349A1 Amorphous paroxetine compositon |
| 05/03/2001 | WO2001030348A1 Use of substance p antagonists for influencing the circadian timing system |
| 05/03/2001 | WO2001030347A1 Treatment or prevention of hypotension and shock |
| 05/03/2001 | WO2001030346A1 Treatment of dyskinesia |
| 05/03/2001 | WO2001030345A1 Clonidine preparations |
| 05/03/2001 | WO2001030344A1 Indole-3-carbinol (i3c) derivatives |
| 05/03/2001 | WO2001030343A1 Pharmaceuticals for treating obesity |
| 05/03/2001 | WO2001030342A1 Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| 05/03/2001 | WO2001030341A1 Cyclooxygenase-2 expression inhibitors |
| 05/03/2001 | WO2001030340A1 Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage |
| 05/03/2001 | WO2001030339A1 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| 05/03/2001 | WO2001030338A2 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation |
| 05/03/2001 | WO2001030337A2 Ophthalmic formulation of dopamine antagonists |
| 05/03/2001 | WO2001030336A2 Pharmaceutical formulations comprising resveratrol and use thereof |
| 05/03/2001 | WO2001030335A2 Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| 05/03/2001 | WO2001030334A2 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation |
| 05/03/2001 | WO2001030333A2 Tissue factor antagonists and methods of use thereof |
| 05/03/2001 | WO2001030332A2 Methods of protecting neuronal function |
| 05/03/2001 | WO2001030330A2 Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| 05/03/2001 | WO2001030329A2 Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction |
| 05/03/2001 | WO2001030328A2 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | WO2001030327A2 Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of ischaemic conditions |
| 05/03/2001 | WO2001030326A1 Treatment of emphysema using rar selective retinoid agonists |
| 05/03/2001 | WO2001030324A2 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia |
| 05/03/2001 | WO2001030323A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 05/03/2001 | WO2001030321A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 05/03/2001 | WO2001030319A1 New and improved formulation for paclitaxel |
| 05/03/2001 | WO2001030318A1 Oral solution containing galanthamine and a sweetening agent |
| 05/03/2001 | WO2001030317A1 Treatment and prevention of herpes simplex infections |
| 05/03/2001 | WO2001030316A2 Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime |
| 05/03/2001 | WO2001030287A1 Local prevention or amelioration of pain from surgically closed wounds |
| 05/03/2001 | WO2001030151A1 Methods of treating hair loss comprising administering indoline compound |
| 05/03/2001 | WO2001030149A1 Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | WO2001030148A1 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | WO2001012607A3 Pharmaceutical compositions comprising 4-quinolones for treating cancers |
| 05/03/2001 | WO2001002423A3 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 05/03/2001 | WO2000077168A3 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS |
| 05/03/2001 | WO2000071165A3 Use of chimeric mutational vectors to change endogenous sequences in solid tissues |
| 05/03/2001 | WO2000066546A3 Monofluoroalkyl derivatives |
| 05/03/2001 | WO2000066164A8 Contraceptive compositions containing antiprogestinic and progestinic |
| 05/03/2001 | WO2000066107A3 Antimalarian agents for the treatment of asthma |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | WO2000064977A8 In situ forming hydrogels |
| 05/03/2001 | WO2000064405A3 Treating hair by targeting enzymes |
| 05/03/2001 | WO2000063245A3 Variant of the plasmodium merozoite surface protein (msp-1) and vaccine comprising said variant |
| 05/03/2001 | WO2000056298A3 Treatment of lyme disease with polysulfated glycosaminoglycan formulations |
| 05/03/2001 | WO2000054785A3 Stabilized bicyclo[3.3.1]nonenes and methods of use |
| 05/03/2001 | WO2000004875A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 05/03/2001 | WO1999059544A3 Orally disintegrable tablets |
| 05/03/2001 | WO1998043637A9 Peroxynitrite decomposition catalyst |
| 05/03/2001 | WO1995003798A3 USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM |
| 05/03/2001 | US20010000786 Administering to an obese canine a low supplemental amount of L-carnitine to promote weight loss, increase the lean body mass, enhance satiety and reduce voluntary food intake |
| 05/03/2001 | US20010000785 Attaching a bioeffecting agent to a substrate with an anchor provided by a linker compound which also forms a cleavable linkage so that the drug has a sustained release; anti-thrombogenic, -imicrobial, -inflammatory agents |
| 05/03/2001 | US20010000784 Administering a diester of an N- or N,N'-mono- or diacyl or peptidyl residue of cystine; a food, nutrient or infusion; patient in a cachectic condition; antitumor, -carcinogenic -diabetes agents; gastrointestinal inflammatory diseases |
| 05/03/2001 | US20010000731 Administration to a patient for prophylaxis and treatment of varicose veins and hemorrhoids an effective amount of an isoquinoline alkaloid or derivatives from the plant by solvent extraction |
| 05/03/2001 | US20010000730 Method of enhancing the efficacy of anti-tumor agents |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951702A1 Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-amino-3,4-dihydro-quinazolines for the preparation of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951701A1 Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten Use of 2-imidazolyl-substituted carbinols of manufacturing a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 05/03/2001 | DE19951671A1 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist and its use as an endothelin antagonist |
| 05/03/2001 | DE19951418A1 Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid Process for the preparation of N- (4,5-Bismethansulfonyl-2-methyl-benzoyl) guanidine, hydrochloride |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE19949202A1 Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure Transdermal therapeutic system for the delivery of acetylsalicylic acid and / or salicylic acid |
| 05/03/2001 | DE19949179A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid |
| 05/03/2001 | DE10038203A1 Implantable active agent depot, useful e.g. in local tumor treatment or gene therapy, comprising drug-containing, cubic phase forming lipid matrix containing modifier molecule to control release kinetics |
| 05/03/2001 | CA2721011A1 Modified gp100 and uses thereof |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389522A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 05/03/2001 | CA2389319A1 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
| 05/03/2001 | CA2389191A1 Hygromycin derivatives |
| 05/03/2001 | CA2389181A1 6-methoxy-2-napthylacetic acid prodrugs for treating inflammation |
| 05/03/2001 | CA2389171A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | CA2389169A1 Novel limonoids for use particularly in the treatment of cancer and method for producing the same |
| 05/03/2001 | CA2389034A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2389019A1 Hygromycin a prodrugs |
| 05/03/2001 | CA2389012A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | CA2388998A1 Treatment of cancer |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388965A1 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 05/03/2001 | CA2388956A1 Use of 2-imidazolyl substituted carbinols for production of a medicament for treatment or prophylaxis of ischaemic conditions |
| 05/03/2001 | CA2388950A1 Nucleic acids of the human abc1 gene and their therapeutic and diagnostic application |
| 05/03/2001 | CA2388942A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | CA2388924A1 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 05/03/2001 | CA2388724A1 Oral glutamine in the prevention of neonatal necrotizing enterocolitis and other gastrointestinal mucosal damage |
| 05/03/2001 | CA2388613A1 New and improved formulation for paclitaxel |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |